Catalog Advanced Search
-
Contains 2 Component(s) Includes a Live Web Event on 08/12/2026 at 1:00 PM (EDT)
Students, Trainees & Early-stage Professionals are encouraged to attend this webinar and hear from a diverse background of panelists as they share various elements of their career journeys and pivotal decisions related to mentorship, leadership, academic excellence and networking that lead to career growth and empowerment.
2026 ACCP Peer Review: Influence Up, Down & Across: Practical Toolkit of Leadership Skills for Every Career Stage - LIVE
Live Session: Wednesday, August 12th, 2026, from 1:00 to 2:00 PM ET
On Demand: Wednesday, August 12th, 2026
Target audience:
Students, Trainees & Early-stage Professionals (1 - 10 years in first, full-time position)
Description:
Students, Trainees & Early-stage Professionals are encouraged to attend this webinar and hear from a diverse background of panelists as they share various elements of their career journeys and pivotal decisions related to mentorship, leadership, academic excellence and networking that lead to career growth and empowerment.
Kristina M. Brooks
Assistant Professor
University of Colorado Anschutz Medical Campus
Kristina Brooks, PharmD is an Assistant Professor in the Department of Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus and Co-Director of the Colorado Antiviral Pharmacology Laboratory. Her research is focused on the clinical pharmacology of therapeutics in infants, children and pregnant women, primarily those with HIV and related coinfections. Dr. Brooks is highly involved in multiple studies through the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network as a pharmacologist and specialty lab director. She is also a member of the DHHS Perinatal and Pediatric HIV Guidelines Panels.
Myong-Jin (MJ) Kim, PharmD
Director
US Food & Drug Administration
Dr. Myong-Jin (MJ) Kim is director of Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, CDER, FDA. MJ leads the group that leverages expertise in clinical pharmacology, formulation science, and human subject protection to conduct research that ensures therapeutic equivalence of generic versions of oral drug products, and to develop product-specific guidances for generic drug developers. She recently served as the FDA Deputy Topic Lead for the ICH Expert Working Group on M13: Bioequivalence for Immediate Release Solid Oral Dosage Forms. MJ graduated from Georgia Institute of Technology in Atlanta, GA, with a Bachelor of Science in chemistry. Subsequently, she received a Doctor of Pharmacy from the Temple University School of Pharmacy in Philadelphia, PA and completed her postdoctoral training in Clinical Pharmacology at Bassett Healthcare in Cooperstown, NY. MJ is currently serving as the Secretary of the American College of Clinical Pharmacology
Ahmed Nader
Senior Director & Research Fellow, CPMS-VxID TA Head (Interim)
GlaxoSmithKline plc
Ahmed Nader Executive Director, Clinical Pharmacology and Quantitative Medicine (CPQM), HBV and CV/Metabolic Comorbidities Ahmed Nader is an Executive Director in Clinical Pharmacology and Quantitative Medicine (CPQM) at GSK, where he leads CPQM support for HBV and cardiovascular and metabolic comorbidities. Since joining GSK five years ago, he has led clinical pharmacology and quantitative medicine teams across high-priority development programs, with a focus on integrating model-informed drug development, quantitative systems pharmacology, and data-driven decision making. Ahmed holds a PhD and MSc in Clinical Pharmacology from Purdue University and previously spent seven years at AbbVie supporting programs in Immunology and Specialty Medicine. His work is centered on applying quantitative clinical pharmacology to accelerate development, strengthen evidence generation, and inform strategic portfolio decisions.
James Ousey
Principal Research Scientist, Modeling and Simulation
AbbVie
Dr. James Ousey is a Principal Research Scientist, Modeling and Simulation, at AbbVie, where he supports the preclinical to clinical translation of locally delivered therapeutics. Dr. Ousey earned a Ph.D. in Biochemistry from Caltech and has previous clinical pharmacology and pharmacometrics experience from prior roles at Pfizer and Arrowhead Pharmaceuticals. As a co-chair of the ACCP Student, Trainee, & Early-stage Professionals (STEP) Committee, Dr. Ousey is committed to facilitating the professional growth of students and trainees in clinical pharmacology and in celebrating the successes of those embarking on their careers.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register
-
Contains 32 Component(s), Includes Credits
The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.
Registration and Pricing
The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.
To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact INFO@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.
Requirements for Credits
All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated in their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits uploaded to the CPE Monitor.
CE Expiration 12/31/2029
-
You must log in to register
- User - $75
- Member - Free!
- More Information
-
You must log in to register
-
Contains 4 Component(s), Includes Credits
Learners who complete this activity will have strengthened knowledge of emerging digital health technologies and their application in clinical care and research. This activity reviews the convergence of extended reality (XR), artificial intelligence (AI), biosensing and digital twin technologies to enable more objective assessment, personalized interventions and improved patient outcomes. Content covers digital therapeutics, including regulatory pathways and reimbursement considerations, with emphasis on AI-driven, adaptive models and key challenges such as data variability, subjectivity of health outcomes and algorithmic fairness. This activity is designed to increase knowledge of digital health technologies and their potential to enhance clinical decision-making, patient monitoring and precision medicine approaches.
2026 ACCP/UCSF Digital Health Webinar
Live Session: Wednesday, April 29nd, 2026, from 1:00 to 2:30 PM ET
On Demand: April 29th, 2026 to April 29th, 2029
Why is this webinar important to your practice?
Learners who complete this activity will have strengthened knowledge of emerging digital health technologies and their application in clinical care and research. This activity reviews the convergence of extended reality (XR), artificial intelligence (AI), biosensing and digital twin technologies to enable more objective assessment, personalized interventions and improved patient outcomes. Content covers digital therapeutics, including regulatory pathways and reimbursement considerations, with emphasis on AI-driven, adaptive models and key challenges such as data variability, subjectivity of health outcomes and algorithmic fairness. This activity is designed to increase knowledge of digital health technologies and their potential to enhance clinical decision-making, patient monitoring and precision medicine approaches.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals interested in the application of digital health technologies in patient care.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe the key components of digital health technologies and their roles in clinical care;
- Explain the classification, regulatory pathways and reimbursement considerations for digital therapeutics;
- Identify opportunities and considerations for integrating digital health technologies into clinical practice, including workflow, safety, equity and patient monitoring.
Walter Greenleaf
Research & Innovations Director
Stanford University
Walter Greenleaf, Ph.D. is a neuroscientist and a medical technology developer working at Stanford University. Walter is considered a leading authority in the fields of digital medicine, wearable sensors, and medical virtual reality technology.
He is an advisor to Stanford University’s Virtual Human Interaction Lab (VHIL), to the Stanford Wearable Electronics (eWear) Program, the Stanford VR & Immersive Technology (VR-IT) Clinic, as well as the Stanford Medical Mixed Reality Center.
In addition to his research and development work at Stanford, Walter serves on the Science Advisory Board for healthcare product companies such as Abbott Labs, Penumbra, and Interaxon. Walter was the founding Chief Science Officer for Pear Therapeutics, a pioneering company in SaMD. He currently advises several venture investment firms and healthcare networks about digital health assessment and therapeutic systems.
Peter Washington
Assistant Professor
University of California, San Francisco
Dr. Peter Washington, PI of the UCSF TECH Lab (techlab.ucsf.edu), is an Assistant Professor in the Division of Clinical Informatics and Digital Transformation (DoC-IT) in the Department of Medicine at the University of California, San Francisco (UCSF). Dr. Washington's research, funded by the NIH, NSF, Weill Neurohub, and foundations, focuses on developing digital diagnostics and digital therapeutics for a wide range of health conditions and addressing fundamental human-centered AI challenges on the way towards creating these digital health innovations. He holds a PhD in Bioengineering from Stanford, MS in Computer Science from Rice, and BA in Computer Science from Rice.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 6 Component(s), Includes Credits
Learners that complete this webinar will have enhanced knowledge of the impact of hepatic impairment on drug metabolism and pharmacokinetics. This activity reviews the pathophysiology of liver disease and its effects on hepatic drug clearance, along with current approaches to assessing hepatic function, including the Child-Pugh classification, MELD score and emerging noninvasive techniques. Emphasis is placed on how hepatic impairment contributes to variability in drug exposure and informs dose selection, with application to clinical pharmacology and medications used in patients with liver dysfunction. This activity is designed to enhance knowledge of hepatic function assessment, interpretation of pharmacokinetic changes and application of evidence-informed dosing strategies to optimize patient outcomes.
2026 ACCP Virtual Journal Club Webinar: Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment
Live Session: Wednesday, April 22nd, 2026, from 12:00 to 1:00 PM ET
On Demand: April 22nd, 2026 to April 22nd, 2029
Why is this webinar important to your practice?
Learners that complete this webinar will have enhanced knowledge of the impact of hepatic impairment on drug metabolism and pharmacokinetics. This activity reviews the pathophysiology of liver disease and its effects on hepatic drug clearance, along with current approaches to assessing hepatic function, including the Child-Pugh classification, MELD score and emerging noninvasive techniques. Emphasis is placed on how hepatic impairment contributes to variability in drug exposure and informs dose selection, with application to clinical pharmacology and medications used in patients with liver dysfunction. This activity is designed to enhance knowledge of hepatic function assessment, interpretation of pharmacokinetic changes and application of evidence-informed dosing strategies to optimize patient outcomes.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals involved in clinical pharmacology and the care of patients with hepatic impairment.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe the pathophysiologic mechanisms of hepatic impairment (e.g., fibrosis, cirrhosis, inflammation) and their impact on hepatic drug metabolism and transport;
- Discuss the challenges and limitations of the current scales and scoring system to assess hepatic impairment;
- Explain the impact of hepatic impairment on pharmacokinetic parameters, including drug clearance, protein binding, and hepatic extraction.
Andrew Talal
Professor of Medicine
University at Buffalo, State University of New York
Andrew Talal, MD, MPH is Professor of Medicine at SUNY, University at Buffalo, a physician-scientist, and board-certified gastroenterologist with >30 years evaluating liver drug metabolism and studying how to improve medication access among underserved populations. He recently completed a stepped wedge, randomized controlled trial of facilitated telemedicine for HCV treatment integrated into opioid treatment programs. The study resulted in a 2-fold improvement in HCV cure compared to offsite referral as described in a JAMA publication. The study received a 2025 Top 10 Clinical Research Achievement Award and one of three Distinguished Clinical Study awards by the Clinical Research Forum. Dr. Talal was appointed by the New York Governor to the New York State HCV Elimination Task Force, and he serves on the NYS HCV Guidelines committee. Dr. Talal has recently been appointed to the Center for Medicare and Medicaid Service’s Technical Expert Panel for Eligible Clinician Electronic Clinical Quality Measures Program.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
- Describe the pathophysiologic mechanisms of hepatic impairment (e.g., fibrosis, cirrhosis, inflammation) and their impact on hepatic drug metabolism and transport;
-
Contains 3 Component(s)
This webinar addresses advanced Exposure-Response (E-R) analysis strategies to support industrial drug development and evaluate regulatory expectations through real-world case examples. Learners who complete this activity will enhance their knowledge of advanced E-R analysis, interpreting regulatory expectations and integrating case-based best practices.
2026 ACCP STEP & ESP Webinar: Exposure-Response Analysis Across the Drug Development Continuum: Case Examples from Industry & Regulatory Perspective
Live Session: Wednesday, March 18th, 2026, from 1:00 to 2:00 PM ET
On Demand: March 18th, 2026 to March 18th, 2029
Target audience:
Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals who are interested in Exposure-Response (E-R) analysis and practical strategies that can be applied within regulatory, industry, and academic settings.
Objectives
After completing this activity, the learner will be able to:
- Identify common challenges and key considerations for implementing E-R analyses in drug development programs;
- Interpret E-R data to inform dosing strategies and support drug development decision-making;
- Discuss the regulatory expectations on implementation of E-R analyses in regulatory reviews;
Description:
This webinar addresses advanced Exposure-Response (E-R) analysis strategies to support industrial drug development and evaluate regulatory expectations through real-world case examples. Learners who complete this activity will enhance their knowledge of advanced E-R analysis, interpreting regulatory expectations and integrating case-based best practices.
Ahmed Salem, PhD
Senior Research Fellow/Senior Director of Clinical Pharmacology & Pharmacometrics
AbbVie, Inc
Ahmed Salem, PhD, FCP is a Senior Research Fellow/Senior Director of Clinical Pharmacology and Pharmacometrics at Abbvie and an adjunct Professor at University of Minnesota. Dr. Salem is a pharmacist and got his PhD in 2010 from the University of Minnesota with a focus on Pharmacometrics and a minor in Biostatistics. In his industry role, Dr. Salem contributed to 15 different FDA and EMA approvals of new drugs, dosage forms or dosage regimens. He has over 230 publications with an i-10 index of 150 and H index of 45 and holds 10 patents in the US and EU. He has worked on over 200 Phase I, II and III clinical trials. Dr Salem is the recipient of the ACCP Tanabe Investigator Award. He was also the recipient of the AAPS High Impact Article Award in addition to other awards and recognition from the IQ-Clinical Pharmacology Leadership Group (CPLG), UMN and AbbVie. He was also selected as a Fellow of ACCP and as a Senior Research Fellow of the Abbvie Community of Science. Dr. Salem has been an invited speaker and chair at multiple conferences such as ACoP, ASCPT, ACCP, FDA workshops.
Hao Zhu, PhD
Director, Division of Pharmacometrics, Office of Clinical Pharmacology
US Food & Drug Administration
Dr. Hao Zhu is the director of the Division of Pharmacometrics, Office of Clinical Pharmacology, at the U.S. FDA. Dr. Zhu also serves as a selection committee member for Model Informed Drug Development, Complex Innovative Trial Design, and Rare Disease Endpoint Advancement meeting programs. His is a member of Digital Health Technology steering committee at the FDA. He is a co-chair for the AI Policy and Review subcommittee at the CDER FDA. Hao is a board member at the newly formed quantitative medicine center of excellence.
Dr. Zhu received his Ph.D. in pharmaceutical sciences and Master in statistics from the University of Florida. Overall, he has more than 20 years of working experience in academia, industry, and regulatory agency. His division reviews the pharmacometrics related submissions and supports pharmacometrics-related policy development.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 3 Component(s)
This webinar addresses gaps in foundational training on core Exposure–Response (E-R) principles relevant to drug development and clinical pharmacology practice. The presentation will explore practical steps to develop credible, fit-for-purpose E-R models aligned with best practices across the drug development continuum. Learners who complete this activity will enhance their knowledge of foundational E-R concepts, strengthening problem solving and critical thinking skills that can be directly applied to clinical pharmacology and regulatory decision-making settings.
2026 ACCP STEP & ESP Webinar: Exposure-Response Analysis Across the Drug Development Continuum: Foundational Principles
Live Session: Wednesday, March 11th, 2026, from 1:00 to 2:00 PM ET
On Demand: March 11th, 2026 to March 11th, 2029
Target audience:
Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals who are interested in the foundational E-R principles and practical strategies that can be applied within regulatory, industry, and academic settings.
Objectives
After completing this activity, the learner will be able to:
- Identify decisions to support, model influence, model risk and model impact;
- Discuss key considerations when creating a qualification plan for Exposure Response (E-R) analyses;
- Identify practical steps to guide the development of credible E-R models.
Description:
This webinar addresses gaps in foundational training on core Exposure–Response (E-R) principles relevant to drug development and clinical pharmacology practice. The presentation will explore practical steps to develop credible, fit-for-purpose E-R models aligned with best practices across the drug development continuum. Learners who complete this activity will enhance their knowledge of foundational E-R concepts, strengthening problem solving and critical thinking skills that can be directly applied to clinical pharmacology and regulatory decision-making settings.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 2 Component(s)
This webinar will examine the role of peer review as a cornerstone of scientific integrity and high-quality biomedical literature. While scientists routinely have their own work peer-reviewed during training and throughout their careers, many have limited exposure to serving as peer reviewers themselves and may not fully understand the process. Join Drs. Joan Korth-Bradley and Mike Fossler as they demystify the peer review process, clarify reviewer expectations and encourage participation in this essential professional responsibility within clinical pharmacology.
2026 ACCP Peer Review: How to Do it to Maintain Quality & Credibility
Live Session: Wednesday, February 11th, 2026, from 1:00 to 2:30 PM ET
On Demand: Wednesday, February 11th, 2026
Target audience:
Clinical pharmacology professionals, including MDs, PharmDs and PhDs or other professionals with little or no experience in performing peer reviews who are interested in learning more about the process.
Description:
This webinar will examine the role of peer review as a cornerstone of scientific integrity and high-quality biomedical literature. While scientists routinely have their own work peer-reviewed during training and throughout their careers, many have limited exposure to serving as peer reviewers themselves and may not fully understand the process. Join Drs. Joan Korth-Bradley and Mike Fossler as they demystify the peer review process, clarify reviewer expectations and encourage participation in this essential professional responsibility within clinical pharmacology.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register
-
Contains 1 Component(s)
This program provides an overview of ACCP requirements and best practices for planning high-quality continuing education (CE) activities that meet accreditation standards for integrity, independence, and educational effectiveness. Participants will review the Standards for Integrity and Independence, including eligibility criteria for organizations, identification and management of relevant financial relationships, and ACCP’s conflict of interest disclosure processes. The activity also addresses foundational elements of CE design, including selection of appropriate activity types, development of measurable learning objectives aligned with Bloom’s Taxonomy, and integration of active learning strategies. Participants will explore principles of effective assessment design, with an emphasis on distinguishing knowledge-based versus application-based assessments, providing meaningful learner feedback, and avoiding common pitfalls in question writing. Upon completion, learners will have a clearer understanding of how to develop compliant, learner-centered CE activities that align educational content, instructional methods, and assessment strategies to support independent, evidence-based clinical pharmacology education.
Essentials of Planning ACCP Continuing Education Activities - On Demand
Why is this webinar important to your practice?
This program provides an overview of ACCP requirements and best practices for planning high-quality continuing education (CE) activities that meet accreditation standards for integrity, independence, and educational effectiveness. Participants will review the Standards for Integrity and Independence, including eligibility criteria for organizations, identification and management of relevant financial relationships, and ACCP’s conflict of interest disclosure processes.
The activity also addresses foundational elements of CE design, including selection of appropriate activity types, development of measurable learning objectives aligned with Bloom’s Taxonomy, and integration of active learning strategies. Participants will explore principles of effective assessment design, with an emphasis on distinguishing knowledge-based versus application-based assessments, providing meaningful learner feedback, and avoiding common pitfalls in question writing.
Upon completion, learners will have a clearer understanding of how to develop compliant, learner-centered CE activities that align educational content, instructional methods, and assessment strategies to support independent, evidence-based clinical pharmacology education.
Target Audience:
This activity is designed for ACCP committee members, staff and volunteers who are involved in the planning, development or review of ACCP continuing education activities, including those responsible for completing CE planning documentation, developing learning objectives and supporting compliant assessment design.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe ACCP requirements for planning independent continuing education activities, including criteria for eligible and ineligible organizations.
- Apply ACCP guidelines to develop measurable learning objectives that align with the selected CE activity type and accreditation expectations.
- Demonstrate competence in selecting appropriate assessment methods and writing compliant assessment questions that align with stated learning objectives.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 48 Component(s), Includes Credits
The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.
Registration and Pricing
The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.
To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact INFO@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.
Requirements for Credits
All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated in their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits uploaded to the CPE Monitor.
CE Expiration 12/31/2028
-
You must log in to register
- User - $75
- Member - Free!
- More Information
-
You must log in to register
-
Contains 5 Component(s), Includes Credits
This webinar will increase learner knowledge of the effects of diet-and-exercise-induced weight loss on drug-metabolizing enzymes and gastric emptying in patients with obesity. The program will cover drug metabolizing enzymes are affected by diet-and-exercise-induced weight loss in patients with obesity. Learners that complete this webinar will recognize patients with obesity can have lower CYP1A2, CYP2C19, and CYP3A4 activity that counterintuitively implies the need for lower doses of drugs metabolized by these pathways.
2025 ACCP Virtual Journal Club Webinar: Examining the Impact of Diet-and-Exercise-Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity - On Demand
Live Session: Thursday, October 9th, 2025, from 12:00 to 1:00 PM ET
On Demand: October 9th, 2025 to October 9th, 2028
Why is this webinar important to your practice?
This webinar will increase learner knowledge of the effects of diet-and-exercise-induced weight loss on drug-metabolizing enzymes and gastric emptying in patients with obesity. The program will cover drug metabolizing enzymes are affected by diet-and-exercise-induced weight loss in patients with obesity. Learners that complete this webinar will recognize patients with obesity can have lower CYP1A2, CYP2C19, and CYP3A4 activity that counterintuitively implies the need for lower doses of drugs metabolized by these pathways.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in the impact of diet & exercise-induced weight loss on patients with obesity.
Learning Objectives
After completing this activity, the learner will be able to:
- List at least one cytochrome (CYP) enzyme whereby activity increased after weight loss;
- Define the parameter used to assess gastric emptying time;
- Identify at least one single time point metabolic ratio that correlated with exposure (AUC) ratio.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information